[Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease]

Clin Ter. 2000 Jul-Aug;151(4):301-6.
[Article in Italian]

Abstract

Glycoprotein IIb-IIIa receptor inhibitors are the newest anti-platelets drugs currently used in patients with coronary artery disease. We examined mechanisms of their action and different pharmacokinetic and pharmacodynamic characteristics of the four glycoprotein IIb-IIIa antagonists evaluated in randomized, controlled and multicenter trials. We reviewed results of these trials in the settings of percutaneous revascularizations procedures or unstable coronary syndromes. Platelet glycoprotein IIb-IIIa receptor inhibitors reduced incidence of cardiac death and myocardial infarction during the short- and midterm, and benefit was greater in: a) patients undergoing coronary angioplasty with or without stent implantation, particularly in the presence of unstable angina, diabetes or complex and diffuse coronary artery disease; b) as a direct therapy of unstable coronary syndromes, particularly in patients with refractory angina, diabetes and elevated Troponin; more recently they have been used as adjuvant therapy in acute myocardial infarction. Infusion of these drugs was not associated with higher rates of major bleedings.

Publication types

  • Review

MeSH terms

  • Abciximab
  • Acetates / therapeutic use
  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal / therapeutic use
  • Diabetes Complications
  • Eptifibatide
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Multicenter Studies as Topic
  • Myocardial Ischemia / blood
  • Myocardial Ischemia / complications
  • Myocardial Ischemia / drug therapy*
  • Myocardial Ischemia / mortality
  • Peptides / therapeutic use
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Platelet Glycoprotein GPIIb-IIIa Complex / metabolism*
  • Randomized Controlled Trials as Topic
  • Stents
  • Survival Analysis
  • Syndrome
  • Tirofiban
  • Treatment Outcome
  • Troponin / blood
  • Tyrosine / analogs & derivatives*
  • Tyrosine / therapeutic use

Substances

  • Acetates
  • Antibodies, Monoclonal
  • Fibrinolytic Agents
  • Immunoglobulin Fab Fragments
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Troponin
  • Tyrosine
  • lamifiban
  • Tirofiban
  • Eptifibatide
  • Abciximab